References

Classification criteria for spondyloarthropathies

10.5312/wjo.v2.i12.107 · 2011 · External reference

Unresolved reference

External reference

Temporal trends in the disease burden of osteoarthritis from 1990 to 2019, and projections until 2030

10.1371/journal.pone.0288561 · 2023 · External reference

Current unmet needs in spondyloarthritis

10.1007/s11926-019-0844-7 · 2019 · External reference

Year in review in axial spondyloarthritis clinical research and guidelines: SPARTAN 2023 annual meeting proceedings

10.1007/s11926-024-01134-z · 2024 · External reference

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

10.1136/ard-2022-223296 · 2023 · External reference

Efficacy and safety of IL inhibitors, TNF-α inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: a systematic review and Bayesian network meta-analysis

10.21037/atm-23-195 · 2023 · External reference

Driving down the cost of biologics: lessons from a nationalised health-care system

10.1016/s0140-6736(24)02151-2 · 2024 · External reference

Treatment strategies for spondyloarthritis: implementation of precision medicine – or “one size fits all” concept

10.1016/j.autrev.2024.103638 · 2024 · External reference

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: real-world data from the BIOBADASER registry

10.1016/j.reuma.2025.501872 · 2025 · External reference

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A

10.2147/jir.s100940 · 2016 · External reference

Ixekizumab

2025 · External reference

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 r

10.1016/s0140-6736(18)31946-9 · 2018 · External reference

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

10.1016/s0140-6736(19)32971-x · 2020 · External reference

Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor nec

10.1002/art.40753 · 2019 · External reference

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

10.1186/s13075-020-02388-5 · 2021 · External reference

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

10.1186/s13075-019-1831-0 · 2019 · External reference

Long-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

10.1186/s13075-023-03257-7 · 2024 · External reference

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

10.1186/s13075-020-2099-0 · 2020 · External reference

Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program

10.3899/jrheum.221022 · 2023 · External reference

Human leukocyte antigen B27-negative axial spondyloarthritis: what do we know

10.1002/acr2.11555 · 2023 · External reference

HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry

10.1007/s10067-022-06490-8 · 2023 · External reference

Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts

10.1111/jdv.15787 · 2020 · External reference

Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases

10.1093/rheumatology/kev374 · 2015 · External reference

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

10.1080/09546634.2022.2082354 · 2022 · External reference

Retention rate of ixekizumab in psoriatic arthritis: a real-world study

10.3390/jpm14070716 · 2024 · External reference

Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry

10.1111/dth.14808 · 2021 · External reference

Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab

10.1016/j.jaad.2019.11.015 · 2020 · External reference

Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis

10.1093/rap/rkae018 · 2024 · External reference

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST

10.1136/rmdopen-2021-002165 · 2022 · External reference

Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program

10.3899/jrheum.221022 · 2023 · External reference

Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence

10.1007/s40259-020-00442-x · 2020 · External reference

Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis

10.1007/s40265-024-02028-1 · 2024 · External reference

Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis

10.1186/s13075-020-02208-w · 2020 · External reference

Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials

10.1155/2019/2546161 · 2019 · External reference

A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis

10.1007/s10067-020-04970-3 · 2020 · External reference

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

10.1016/j.jaad.2019.03.048 · 2019 · External reference

Drug retention rate and factors associated with discontinuation of interleukin-17 inhibitors in patients with axial spondyloarthritis

10.3349/ymj.2023.0151 · 2023 · External reference

Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease

10.1007/s00296-023-05289-3 · 2023 · External reference

Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: real-life experience from a resistant population

10.2147/btt.s326792 · 2021 · External reference

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study

10.1002/art.23333 · 2008 · External reference

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies

10.1136/annrheumdis-2019-215356 · 2019 · External reference

The IL-17/IL-23 axis and its genetic contribution to psoriatic arthritis

10.3389/fimmu.2020.596086 · 2021 · External reference

The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis

10.1007/s12016-018-8702-3 · 2018 · External reference

Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers

10.1016/j.autrev.2021.102760 · 2021 · External reference

Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis

10.1056/nejmoa1505066 · 2015 · External reference

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

10.1136/annrheumdis-2012-201933 · 2013 · External reference

Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice

10.1186/s13075-019-1908-9 · 2019 · External reference

Anti-IL-17 agents in the treatment of axial spondyloarthritis

10.2147/itt.s259126 · 2021 · External reference

Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis

10.1136/ard.2010.129726 · 2010 · External reference

Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review

10.3389/fimmu.2023.993057 · 2023 · External reference

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

10.1093/rheumatology/keaa189 · 2020 · External reference

Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure

10.1007/s13555-022-00743-9 · 2022 · External reference